Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam H. Rogers
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.73
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.25
Financials
Net Income
$-29.99MEBITDA
$-12.51MFree Cash Flow
$-5.81MEPS (diluted)
$-0.33-36766.7%Shares Outstanding (diluted)
92.44M+239.8%Operating Expenses
$12.51MCash & Debt
$86.93MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-44.12M | $-0.61 |
| 2024 | $0.00 | $-23.99M | $-0.36 |
| 2023 | $0.00 | $-22.38M | $-0.37 |
| 2022 | $0.00 | $-20.54M | $-0.39 |
| 2021 | $0.00 | $-12.82M | $-0.33 |
| 2020 | $0.00 | $-11.21M | $-0.34 |
| 2019 | $0.00 | $-10.03M | $-0.39 |
| 2018 | $0.00 | $-1.35M | $-0.05 |
| 2017 | $0.00 | $-12.0K | $0.00 |
Valuation
NGENhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·4d ago·Negative
…l cord injury. RESTORE is powered to detect a 2.5-point treatment effect, with no interim efficacy analysis planned, making the outcome binary until topline results. NGEN is funded through the RESTORE topline readout in 1H 2028, but dilution risk remains due to a significant increase in share count and an unused $50M ATM facility.
View source ↗ - Newsseekingalpha.com·6d ago·Negative
NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
…te Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financi…
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
NervGen to Host Inaugural R&D Day on September 30, 2026 VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that it will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise -68.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.37 vs $-0.06miss
- Mon, May 18$-0.01 vs $-0.07beat
- Thu, Apr 2$-0.26 vs $-0.06miss
- Tue, Nov 25$-0.04 vs $-0.06beat
- Wed, Aug 27$-0.09 vs $-0.05miss
- Thu, May 15$-0.04 vs $-0.06beat
Estimates and results for NGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NGEN officers and directors.
- Bought
- —
- Sold
- $2.0m
0 trades
74 trades
- Dreismann Heinersold
- Dreismann Heinersold
- Birndorf Howard Csold
- Birndorf Howard Csold
- Birndorf Howard Csold
- Birndorf Howard Csold
- Birndorf Howard Csold
- Birndorf Howard Csold
26 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NGEN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.